SUMMARY The efficacy of ranitidine (150 mg nocte), and sulcralfate (1 g tds) as maintenance therapy to prevent gastric ulcer relapse was evaluated in a 12 month trial in 363 patients. The relapse rates were 8.8% at three months, 14.7% at six months, 18/1% at nine months, and 21V0% at 12 months for the ranitidine group and 1477%, 21/3%, 29.9%, and 30.2% respectively for the sucralfate group. At nine and 12 months the cumulative relapse rates for the ranitidine group were significantly lower than those for the sucralfate group (p<005). In both groups ulcers recurred mainly from red scars observed at the endoscopic scarring stage. This indicated the necessity of drug treatment up to the white scar stage. The results suggest that ranitidine is effective in preventing gastric ulcer relapse.
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Gastric acid is generally considered to be a key factor in peptic ulcer development and the histamine H receptor blockers which inhibit its formation have become standard therapy for treatment of both duodenal and gastric ulcer.
On average duodenal ulcer patients secrete more gastric acid than healthy control subjects. Many clinical trials have therefore been conducted with H, blockers to evaluate their use as to prevent duodenal ulcer relapse.Ì n contrast gastric ulcer patients as a group secrete less acid than normal and are usually considered to have an imbalance between agressive and defensive factors resulting from impaired gastric defence.
This imbalance may, in theory, be rectified by therapeutic intervention which acts to increase mucosal defence or to inhibit gastric acid and pepsin. As there is no definitive information on the relative merits of these two approaches to treatment we have conducted a large clinical trial to compare the effects of ranitidine, an agent which inhibits gastric acid secretion and sucralfate, a mucosal protective agent in the prevention of gastric ulcer relapse.
Patients whose gastric ulcers had healed after any active treatment were recruited if endoscopy had confirmed the ulcer and its healing and if they were suitable for outpatient management.
DOSAGE AND ADMINISTRAIION
The effects of ranitidine (Glaxo, UK), 150 mg/day at bedtime, and sucralfate (Chugai Pharmaceutical Co, Japan), 1 g tds, on the rate of gastric ulcer relapse were compared in a one year maintenlance trial conducted by investigators in 72 centres.
Each patient received either four 250 mg tablets of sucralfate three times a day (before breakfast and lunch and at bedtime) or four placebo tablets before breakfast and lunch and one 150 mg ranitidine tablet with three placebo tablets at bedtime. In order to maintain blindness, all the drugs and placebo tablets were prepared in packages which were indistinguishable in their appearance. The patients were enrolled irrespective of their previous ulcer treatment, but patients with concurrent duodenal ulceration or those with a linear ulcer were excluded. Also excluded were patients who were or might be pregnant or lactating.
Use of all other anti-ulcer drugs was prohibited as were known ulcerogenic agents such as oral steroids and non-steroidal anti-inflammatory drugs. Seventeen subjects were excluded for the reasons presented in Table 1 . Table 2 shows the demographic data for the remaining 346 subjects (171 received ranitidine and 175 sucralfate) who were eligible for analysis, and no significant differences were noted for any of those factors. Previous ulcer treatment for the healing phase is shown in Table 3 . In both drug groups many subjects had been treated with HWreceptor blockers but there was no difference in the distribution of any of the treatments. Also, in most cases in both groups, a red scar stage was detected at the initial endoscopic examination (Table 2 ).
CUMUIATIVE RELAPSE RAFES All the adverse effects developed during the first six weeks of the trial. Those symptoms resolved or were alleviated in all cases as the drug treatment was continued or stopped.
No clinically significant changes were detected in Sucralfate, the control drug for this trial, is widely prescribed in Japan for gastric ulcer treatment, and several papers'" have dealt with its use as maintenance therapy. In one of those reports, Marks et al '3 commented that the recommended therapeutic dosage for satisfactory prevention of gastric ulcer relapse is 3 g/day, given as 1 g between breakfast and lunch and 2 g before bedtime.
In our study, ranitidine 150 mg/day and sucralfate 1 g tds (method of administration differed from that reported by Marks et al), were compared for their effects on gastric ulcer relapse. As a result, ranitidine showed a cumulative relapse rate for one year of 21-0%, and its effect on ulcer relapse was significantly superior to sucralfate (p<0-05) after nine and 12 months treatment. In the studies by Boyd et al" and Cockel et al," the cumulative relapse rates for one year were also about 20% . For sucralfate, Marks et all4 reported a relapse rate of 16-0% for six months. Our relapse rate of 21-3% for six months was similar to their result.
In our study, endoscopic examination was conducted at three monthly intervals and at unscheduled A times whenever the symptoms warranted; this permitted accurate monitoring of asymptomatic recurrence. The total cumulative relapse rate and the cumulative symptomatic relapse rate for the open study of Boyd et al were 22-6% and 14-0%, respectively. Similar relapse rates of 21 -0% and 12-7% were observed in our study, thus elucidating the ratio of symptomatic relapse to asymptomatic relapse of gastric ulcer in ranitidine maintenance therapy. In any case, in our comparative study enrolling a large number of patients, ranitidine, a histamine H2-receptor blockers, showed satisfactory prevention of gastric ulcer relapse, in which a decrease in defensive factors is said to have a strong causal relation, in comparison with sucralfate, which has a mucosal protective action. This finding suggests that ranitidine is an effective drug for gastric ulcer maintenance therapy.
The gastric ulcer relapse rate peaked during the first three months of maintenance therapy, and this may be attributable to many factors, including previous ulcer treatment. Furthermore, there is a question as to whether the relapse observed in the first three months is a genuine relapse of merely incomplete prior healing.
Peptic ulcers are judged as healed by endoscopic confirmation of a scar. Generally, in Japan scars are classified as red scars and white scars. In a study on sucralfate in the prevention of gastric ulcer relapse, Miyake et al' reported that relapse rates are higher from red scars, suggesting that endoscopic characterisation of the scar is useful for predicting ulcer relapse. During our study relapse in both treatment groups was greater in patients with a red scar than those having a white scar. These observations suggest that it may be necessary to continue therapy at the therapeutic dosage until confirmation of a white scar, in contrast with concluding that a red scar is proof of healing.
There is considerable discussion regarding the safety of longterm administration, including maintenance therapy, of histamine H2-receptor blockers, but because they have been clinically available for only 10 years, lifetime safety data are not available. On the other hand, sucralfate has been used for 20 years in Japan without serious side effects; it is a nonsystemic drug and therefore it is a good choice in terms of safety of longterm administration.
All the areas of adverse effects in both drug groups in this study developed during the first three months, and no severe cases were observed throughout the year. For sucralfate, no untoward effects were noted which could have been ascribed to aluminium toxicity. Further studies over a longer period and including a larger number of patients are needed to establish the safety of longterm administration of histamine H2-receptor blockers.
Based on the results of our study, administration of ranitidine, in a dose of 150 mg/day nocte for 12 months is more effective in preventing gastric ulcer relapse than sucralfate, in a dose of I g tds (before breakfast, lunch, and bed-time).
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